Braveheart Bio reported positive results from an open-label randomized Phase 2 dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy (oHCM). Data presented at the American College of Cardiology meeting showed rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint. The company reported meaningful endpoint improvements across dosing levels, positioning BHB-1893 as a potential disease-modifying cardiac myosin inhibitor option in a category where outcomes depend heavily on gradient reduction. Braveheart is now expected to advance discussions around next-stage development. Market participants will focus on durability, safety, and whether the observed hemodynamic effects translate into longer-term clinical benefits.